Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Registration Number
- NCT03011450
- Lead Sponsor
- Kowa Research Institute, Inc.
- Brief Summary
The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients With Fasting High Triglyceride Levels ≥500 mg/dL and \<2000 mg/dL and Mild or Moderate Renal Impairment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 471
-
Able to understand and willing to comply with all study requirements and procedures throughout the duration of the study and give written informed consent;
-
Aged ≥18 years;
-
Patients receiving moderate- or high-intensity statin therapy must meet one of the following criteria¹ unless they have any exceptional conditions (see inclusion criterion 4):
- Aged ≥21 years with clinical atherosclerotic cardiovascular disease (ASCVD) (history of acute coronary syndrome or myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack [TIA] presumed to be of atherosclerotic origin, or peripheral arterial disease or revascularization), on a high-intensity statin (or moderate-intensity statin if not a candidate for high-intensity statin due to safety concerns);
- Aged ≥21 years with a history of LDL-C ≥190 mg/dL, which is not due to secondary modifiable causes, on a high-intensity statin (or moderate-intensity statin if not a candidate for high-intensity statin due to safety concerns);
- Aged 40 to 75 years, inclusive, without clinical ASCVD but with diabetes and a history of LDL-C of 70 to 189 mg/dL, inclusive, on a moderate- or high-intensity statin; or
- Aged 40 to 75 years, inclusive, without clinical ASCVD or diabetes, with a history of LDL-C of 70 to 189 mg/dL, inclusive, with estimated 10-year risk for ASCVD of ≥7.5% by the Pooled Cohort Equation on a moderate- or high-intensity statin;
-
Patients currently on a low-intensity statin or not on a statin, must meet one of the following criteria;
- Patient does not meet any criteria for moderate- or high-intensity statin therapy listed above (see inclusion criteria, 3.a. through 3.d.);
- Patient does meet one or more criteria for moderate- or high-intensity statin therapy listed above (see inclusion criteria 3.a. through 3.d.); but the patient is not a candidate for moderate or high-intensity statin due to safety concerns, or due to partial or complete statin intolerance; or
- Patient does meet one or more criteria for moderate- or high intensity statin therapy listed above (see inclusion criteria 3.b. through 3.d., except for 3.a.); but the patient is not a candidate for moderate or high intensity statin for primary prevention after considering individual risk evaluation (e.g. current LDL C ≤70mg/dL) and patient preference;
-
Fasting TG levels ≥500 mg/dL (5.65 mmol/L) and <2000 mg/dL (22.60 mmol/L) based on the mean of Visit 2 (Week -2) and Visit 3 (Week -1).
- Mild to moderate renal impairment eGFR >= 30mL/min/1.73 and < 90 mL/min/1.73 at Visit 1
- Patients who will require lipid-altering treatments other than study drugs (K-877 or fenofibrate), statins, ezetimibe, or PCSK9 inhibitors during the course of the study. These include bile acid sequestrants, non-study fibrates, niacin (>100 mg/day), omega-3 fatty acids (>1000 mg/day), or any supplements used to alter lipid metabolism including, but not limited to, red rice yeast supplements, garlic supplements, soy isoflavone supplements, sterol/stanol products, or policosanols;
- Body mass index (BMI) >45 kg/m2 at Visit 1 (Week -8 or Week -6);
- Patients with type 1 diabetes mellitus;
- Patients with newly diagnosed (within 3 months prior to Visit 2 [Week -2]) or poorly controlled type 2 diabetes mellitus (T2DM), defined as hemoglobin A1c >9.5% at Visit 1 (Week -8 or Week -6);
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 12 Week Efficacy Placebo (for K-877) K-877 or placebo comparator for 12 weeks 40 week extension K-877 K-877 or fenofibrate comparator for 40 weeks 12 Week Efficacy K-877 K-877 or placebo comparator for 12 weeks 40 week extension Fenofibrate K-877 or fenofibrate comparator for 40 weeks
- Primary Outcome Measures
Name Time Method Percent Change in Fasting TG From Baseline to Week 12 12 Weeks
- Secondary Outcome Measures
Name Time Method Percent Change From Baseline to Week 12 in Ion Mobility (VLDL Cholesterol-Small) 12 Weeks Percent Change From Baseline to Week 12 in Apo A1 12 Weeks Percent Change From Baseline to Week 52 in Apo A2 52 Weeks Percent Change From Baseline to Week 52 in Apo B 52 Weeks Percent Change From Baseline to Week 52 in Apo C2 52 Weeks Percent Change From Baseline to Week 12 in Apo A2 12 Weeks Percent Change From Baseline to Week 12 in Apo B 12 Weeks Percent Change From Baseline to Week 12 in Apo C2 12 Weeks Percent Change From Baseline to Week 52 in Apo E 52 Weeks Change From Baseline to Week 52 in hsCRP 52 Weeks Percent Change From Baseline to Week 12 in HDL-C 12 Weeks Percent Change From Baseline to Week 12 in Non-HDL-C 12 Weeks Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2 52 Weeks Percent Change From Baseline to Week 52 in Ion Mobility (VLDL Cholesterol-Intermediate) 52 Weeks Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo B:Apo A1 52 Weeks Percent Change From Baseline to Week 12 in Remnant Cholesterol 12 Weeks Percent Change From Baseline to Week 12 in Total Cholesterol 12 Weeks Percent Change From Baseline to Week 12 in LDL-C 12 Weeks Percent Change From Baseline to Week 12 in Apo B48 12 Weeks Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Particles-Small) 52 Weeks Percent Change From Baseline to Week 12 in FFAs 12 Weeks Percent Change From Baseline to Week 12 in Apo B100 12 Weeks Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins I) 12 Weeks Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IIIa) 12 Weeks Percent Change From Baseline to Week 12 in Ion Mobility (High Density Lipoproteins 2b) 12 Weeks Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL & Chylomicron Particles-Large) 12 Weeks Two types of lipoprotein particles were analyzed together as one measurement without distinction.
Percent Change From Baseline to Week 12 in Lipoprotein Fraction (HDL Particle Size) 12 Weeks Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of LDL-C:Apo B 12 Weeks Percent Change From Baseline to Week 52 in Remnant Cholesterol 52 Weeks Percent Change From Baseline to Week 52 in Apo A1 52 Weeks Percent Change From Baseline to Week 52 in Non-HDL-C 52 Weeks Change From Baseline to Week 12 in FGF21 12 Weeks Change From Baseline to Week 12 in Lipoprotein Fraction (LDL Particles-Small) 12 Weeks Percent Change From Baseline to Week 12 in Lipoprotein Fraction HDL Cholesterol (Total) 12 Weeks Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of TG:HDL-C 12 Weeks Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL Particles-Medium) 12 Weeks Change From Baseline to Week 12 in Lipoprotein Fraction (LDL Particles-Large) 12 Weeks Percent Change From Baseline to Week 12 in Apo C3 12 Weeks Change From Baseline to Week 12 in hsCRP 12 Weeks Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IVb) 12 Weeks Percent Change From Baseline to Week 12 in Ion Mobility (High Density Lipoproteins 3 and 2a) 12 Weeks Two lipoprotein subclasses, HDL3 and HDL2a, were analyzed together as one measurement without distinction.
Change From Baseline to Week 12 in Lipoprotein Fraction (HDL Particles-Large) 12 Weeks Percent Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL & Chylomicron Triglyceride) 12 Weeks Two types of lipoprotein particles were analyzed together as one measurement without distinction.
Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2 12 Weeks Percent Change From Baseline to Week 12 in Ion Mobility (VLDL Cholesterol-Intermediate) 12 Weeks Percent Change From Baseline to Week 12 in Ion Mobility (Intermediate Density Lipoproteins 2) 12 Weeks Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IVa) 12 Weeks Percent Change From Baseline to Week 12 in Ion Mobility (Diameter of the Major LDL Particle (Å)) 12 Weeks Percent Change From Baseline to Week 12 in Lipoprotein Fraction (HDL Particles) 12 Weeks Change From Baseline to Week 12 in Lipoprotein Fraction (HDL Particles-Medium) 12 Weeks Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of TC:HDL-C 12 Weeks Percent Change From Baseline to Week 52 in Fasting TG 52 Weeks Percent Change From Baseline to Week 52 in HDL-C 52 Weeks Percent Change From Baseline to Week 12 in Apo E 12 Weeks Percent Change From Baseline to Week 12 in Ion Mobility (VLDL Cholesterol-Large) 12 Weeks Percent Change From Baseline to Week 12 in Ion Mobility (Intermediate Density Lipoproteins 1) 12 Weeks Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IIa) 12 Weeks Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IIb) 12 Weeks Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IIIb) 12 Weeks Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IVc) 12 Weeks Percent Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL & Chylomicron Particles) 12 Weeks Two types of lipoprotein particles were analyzed together as one measurement without distinction.
Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL Particles-Small) 12 Weeks Percent Change From Baseline to Week 12 in Lipoprotein Fraction (LDL Particles) 12 Weeks Change From Baseline to Week 12 in Lipoprotein Fraction (IDL Particles) 12 Weeks Change From Baseline to Week 12 in Lipoprotein Fraction (HDL Particles-Small) 12 Weeks Percent Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL Particle Size) 12 Weeks Percent Change From Baseline to Week 12 in Lipoprotein Fraction (LDL Particle Size) 12 Weeks Percent Change From Baseline to Week 12 in Lipoprotein Fraction (Triglyceride) 12 Weeks Percent Change From Baseline to Week 52 in TC 52 Weeks Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo B:Apo A1 12 Weeks Percent Change From Baseline to Week 52 in Apo B100 52 Weeks Percent Change From Baseline to Week 52 in Apo C3 52 Weeks Change From Baseline to Week 52 in FGF21 52 Weeks Percent Change From Baseline to Week 52 in Ion Mobility (VLDL Cholesterol-Large) 52 Weeks Percent Change From Baseline to Week 52 in Ion Mobility (Intermediate Density Lipoproteins 1) 52 Weeks Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IIIa) 52 Weeks Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IIIb) 52 Weeks Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IVb) 52 Weeks Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL & Chylomicron Particles-Large) 52 Weeks Two types of lipoprotein particles were analyzed together as one measurement without distinction.
Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL Particles-Small) 52 Weeks Percent Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Particles) 52 Weeks Percent Change From Baseline to Week 52 in Lipoprotein Fraction (LDL Particle Size) 52 Weeks Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TG:HDL-C 52 Weeks Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C 12 Weeks Percent Change From Baseline to Week 52 in FFAs 52 Weeks Percent Change From Baseline to Week 52 in Apo B48 52 Weeks Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IIb) 52 Weeks Percent Change From Baseline to Week 52 in Ion Mobility (High Density Lipoproteins 2b) 52 Weeks Percent Change From Baseline to Week 52 in LDL-C 52 Weeks Percent Change From Baseline to Week 52 in Ion Mobility (Intermediate Density Lipoproteins 2) 52 Weeks Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IIa) 52 Weeks Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IVa) 52 Weeks Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IVc) 52 Weeks Percent Change From Baseline to Week 52 in Ion Mobility (VLDL Cholesterol-Small) 52 Weeks Percent Change From Baseline to Week 52 in Ion Mobility (High Density Lipoproteins 3 and 2a) 52 Weeks Two lipoprotein subclasses, HDL3 and HDL2a, were analyzed together as one measurement without distinction.
Percent Change From Baseline to Week 52 in Ion Mobility (Diameter of the Major LDL Particle (Å)) 52 Weeks Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins I) 52 Weeks Percent Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL & Chylomicron Particles) 52 Weeks Two types of lipoprotein particles were analyzed together as one measurement without distinction.
Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL Particles-Medium) 52 Weeks Change From Baseline to Week 52 in Lipoprotein Fraction (IDL Particles) 52 Weeks Percent Change From Baseline to Week 52 in Lipoprotein Fraction (LDL Particles) 52 Weeks Change From Baseline to Week 52 in Lipoprotein Fraction (LDL Particles-Large) 52 Weeks Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Particles-Medium) 52 Weeks Percent Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL Particle Size) 52 Weeks Percent Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Particle Size) 52 Weeks Percent Change From Baseline to Week 52 in Lipoprotein Fraction (Triglyceride) 52 Weeks Change From Baseline to Week 52 in Lipoprotein Fraction (LDL Particles-Small) 52 Weeks Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Particles-Large) 52 Weeks Percent Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Cholesterol) 52 Weeks Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C 52 Weeks Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of LDL-C:Apo B 52 Weeks Percent Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL & Chylomicron Triglyceride) 52 Weeks Two types of lipoprotein particles were analyzed together as one measurement without distinction.
Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TC:HDL-C 52 Weeks
Trial Locations
- Locations (236)
South Florida Research Solutions LLC.
🇺🇸Pembroke Pines, Florida, United States
Boyett Health Services Inc
🇺🇸Hamilton, Alabama, United States
Longwood Research - Saadat Ansari, MD, LLC
🇺🇸Huntsville, Alabama, United States
Terence T. Hart, MD
🇺🇸Tuscumbia, Alabama, United States
Phoenix Medical Research Institute, LLC
🇺🇸Peoria, Arizona, United States
iResearch
🇺🇸Decatur, Georgia, United States
Advanced Research Center
🇺🇸Anaheim, California, United States
Catalina Research Institute, LLC
🇺🇸Montclair, California, United States
Pacific Coast Cardiology and Research
🇺🇸Newport Beach, California, United States
Downtown L.A. Research Center, Inc.
🇺🇸Los Angeles, California, United States
Torrance Clinical Research Institute Inc.
🇺🇸Lomita, California, United States
Lucita M. Cruz, MD., Inc.
🇺🇸Norwalk, California, United States
Atlantic Clinical Research Collaborative
🇺🇸Boynton Beach, Florida, United States
ALL Medical Research, LLC
🇺🇸Cooper City, Florida, United States
S & W Clinical Research
🇺🇸Fort Lauderdale, Florida, United States
Indago Research and Health Center
🇺🇸Hialeah, Florida, United States
Advanced Research Institute Inc
🇺🇸New Port Richey, Florida, United States
Jacksonville Impotence Treatment Center
🇺🇸Jacksonville, Florida, United States
AMPM Research Clinic
🇺🇸Miami Gardens, Florida, United States
Ocala Cardiovascular Research
🇺🇸Ocala, Florida, United States
Progressive Medical Research
🇺🇸Port Orange, Florida, United States
Cardiovascular Center of Sarasota
🇺🇸Sarasota, Florida, United States
Columbus Regional Health
🇺🇸Columbus, Georgia, United States
Physicians Research Associates, Inc
🇺🇸Lawrenceville, Georgia, United States
Georgia Institute for Clinical Research
🇺🇸Marietta, Georgia, United States
Endocrine Research Solutions, Inc
🇺🇸Roswell, Georgia, United States
Meridian Clinical Research - Savannah, GA
🇺🇸Savannah, Georgia, United States
Solaris Clinical Research
🇺🇸Meridian, Idaho, United States
Lemah Creek Clinical Research
🇺🇸Burr Ridge, Illinois, United States
Koch Family Medicine
🇺🇸Morton, Illinois, United States
Cedar-Crosse Research Center
🇺🇸Chicago, Illinois, United States
Apex Medical Research
🇺🇸Chicago, Illinois, United States
Community Hospital of Anderson and Madison County, Inc
🇺🇸Anderson, Indiana, United States
American Health Network - Avon Clinical Research Department
🇺🇸Avon, Indiana, United States
Medisphere Medical Research Center
🇺🇸Evansville, Indiana, United States
The Iowa Clinic - Cardiovascular Services
🇺🇸West Des Moines, Iowa, United States
Buynak Clinical Research, P.C.
🇺🇸Valparaiso, Indiana, United States
West Broadway Clinic
🇺🇸Council Bluffs, Iowa, United States
Research Integrity LLC
🇺🇸Owensboro, Kentucky, United States
Clinical Trials Management, LLC - Northshore
🇺🇸Covington, Louisiana, United States
Grace Research, LLC
🇺🇸Huntsville, Texas, United States
Clinical Trials of America, LLC
🇺🇸West Monroe, Louisiana, United States
Maryland Cardiovascular Specialists
🇺🇸Baltimore, Maryland, United States
Regeneris Medical
🇺🇸North Attleboro, Massachusetts, United States
Oakland Medical Research Center
🇺🇸Troy, Michigan, United States
Aa Mrc, Llc
🇺🇸Flint, Michigan, United States
Advance Clinical Research, Inc
🇺🇸Saint Louis, Missouri, United States
Consult and Research Associates
🇺🇸Saint Louis, Missouri, United States
Glacier View Research Institute
🇺🇸Kalispell, Montana, United States
Desert Endocrinology Clinical Research Center
🇺🇸Henderson, Nevada, United States
Lakeshore Primary Care Associate
🇺🇸Hamburg, New York, United States
Mid-Hudson Medical Research, PLLC - Hopewell Junction
🇺🇸New Windsor, New York, United States
Orchard Park Family Practice
🇺🇸Orchard Park, New York, United States
Mid-Hudson Medical Research, PLLC - New Windsor
🇺🇸New Windsor, New York, United States
Diabetes and Endocrinology Consultants, P.C.
🇺🇸Morehead City, North Carolina, United States
Lillestol Research, LLC
🇺🇸Fargo, North Dakota, United States
Alpha Research Associates, LLC
🇺🇸Dayton, Ohio, United States
Aventiv Research, Inc.
🇺🇸Columbus, Ohio, United States
Prestige Clinical Research
🇺🇸Franklin, Ohio, United States
Ohio Clinical Research - Lyndhurst
🇺🇸Lyndhurst, Ohio, United States
Rama Research LLC
🇺🇸Marion, Ohio, United States
RAS Health Ltd
🇺🇸Marion, Ohio, United States
Summit Research Group, LLC
🇺🇸Munroe Falls, Ohio, United States
Ohio Clinical Research, LLC - Willoughby Hills
🇺🇸Willoughby Hills, Ohio, United States
Clinical Research Associates of Central PA, LLC
🇺🇸Altoona, Pennsylvania, United States
Richard M.Kastelic MD and Associates
🇺🇸Johnstown, Pennsylvania, United States
Green and Seidner Family Practice Associates
🇺🇸Lansdale, Pennsylvania, United States
Center for Medical Research, LLC
🇺🇸Providence, Rhode Island, United States
MDFirst Research - Anderson
🇺🇸Anderson, South Carolina, United States
DeGarmo Institute Of Medical Research
🇺🇸Greer, South Carolina, United States
Health Concepts
🇺🇸Rapid City, South Dakota, United States
PMG Research of Bristol, LLC - State
🇺🇸Bristol, Tennessee, United States
New Phase Research & Development
🇺🇸Knoxville, Tennessee, United States
Health Innovation Research Group
🇺🇸Arlington, Texas, United States
Clinical Research Solutions - Smyrna, TN
🇺🇸Smyrna, Tennessee, United States
Holston Medical Group
🇺🇸Kingsport, Tennessee, United States
Inquest Clinical Research
🇺🇸Baytown, Texas, United States
Padre Coast Clinical Research
🇺🇸Corpus Christi, Texas, United States
Protenium Clinical Research, LLC - Dallas
🇺🇸Dallas, Texas, United States
Juno Research, LLC
🇺🇸Katy, Texas, United States
Protenium Clinical Research, LLC
🇺🇸Hurst, Texas, United States
FMC Science
🇺🇸Lampasas, Texas, United States
VA North Texas Health Care System - Dallas VA Medical Center (DVAMC)
🇺🇸Dallas, Texas, United States
Academy of Diabetes, Thyroid and Endocrine, P.A.
🇺🇸El Paso, Texas, United States
Pinnacle Clinical Research
🇺🇸Live Oak, Texas, United States
DCT - McAllen Primary Care, LLC
🇺🇸McAllen, Texas, United States
Manassas Clinical Research Center
🇺🇸Manassas, Virginia, United States
Cardiovascular Associates, Ltd
🇺🇸Virginia Beach, Virginia, United States
York Clinical Research LLC
🇺🇸Norfolk, Virginia, United States
Exemplar Research Inc. - Fairmont, WV
🇺🇸Morgantown, West Virginia, United States
Allegiance Research Specialists, LLC
🇺🇸Wauwatosa, Wisconsin, United States
City Clinical Hospital #1
🇧🇾Minsk, Belarus
Gomel Regional Clinical Center of Cardiology
🇧🇾Gomel, Belarus
Grodno University Hospital
🇧🇾Grodno, Belarus
Mogilev Regional Medical and Diagnostic Center
🇧🇾Mogilev, Belarus
City Clinical Hospital #9
🇧🇾Minsk, Belarus
University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski EAD- First Cardiology Clinic
🇧🇬Pleven, Bulgaria
University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski EAD- Second Cardiology Clinic
🇧🇬Pleven, Bulgaria
MHAT Dr. Bratan Shukjerov
🇧🇬Smolyan, Bulgaria
University Multiprofile Hospital for Active Treatment (UMHAT) Sveti Georgi, EAD - Clinic of Cardiology
🇧🇬Plovdiv, Bulgaria
Multiprofile Hospital For Active Treatment - Dr. Bratan Shukerov AD
🇧🇬Smolyan, Bulgaria
Medicus Services SRO
🇨🇿Brandýs nad Labem, Czechia
Fakultni nemocnice Hradec Kralove, Klinika gerontologicka a metabolicka
🇨🇿Hradec Králové, Czechia
Lipidova poradna
🇨🇿Bílina, Czechia
Ordinace pro choroby srdce a cev
🇨🇿Praha 10, Czechia
Vseobecna fakultni nemocnice v Praze
🇨🇿Praha 2, Czechia
MUDr. Nina Zemkova s.r.o. Interni Ambulance
🇨🇿Uherské Hradište, Czechia
Fakultni nemocnice v Motole
🇨🇿Praha 5, Czechia
Oblastni nemocnice Trutnov, Oddeleni klinicke biochemie
🇨🇿Trutnov, Czechia
Clinic LJ Ltd
🇬🇪Kutaisi, Georgia
Aleksandre Aladashvili Clinic - LLC
🇬🇪Tbilisi, Georgia
Archangel St Michael Multiprofile Clinical Hospital Ltd
🇬🇪Tbilisi, Georgia
Emergency Cardiology Center by Academician G. Chapidze Ltd
🇬🇪Tbilisi, Georgia
Institute of Clinical Cardiology Ltd
🇬🇪Tbilisi, Georgia
Unimed Kakheti - Telavi Referral Hospital LLC
🇬🇪Telavi, Georgia
DRC Gyogyszervizsgalo Kozpont Kft
🇭🇺Balatonfüred, Hungary
DRC Balatongyorok
🇭🇺Balatongyörök, Hungary
Magyar Honvedseg Allami Egeszsegugyi Kozpont, II. sz Belgyogyaszat Osztaly
🇭🇺Budapest, Hungary
Magyar Honvedseg Egeszsegugyi Kozpont
🇭🇺Budapest, Hungary
BKS Research Kft.
🇭🇺Hatvan, Hungary
Debreceni Egyetem Klinikai Kozpont
🇭🇺Debrecen, Hungary
Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz
🇭🇺Székesfehérvár, Hungary
MEDICOME Sp. z o.o.
🇵🇱Oświęcim, Poland
Indywidualna Specjalistyczna Praktyka Lekarska w Dziedzinie Kardiologii, lek. med. Krzysztof Cymerman
🇵🇱Gdynia, Poland
Malopolskie Centrum Alergii i Immunoterapii Allmedis SP Z O O
🇵🇱Krakow, Poland
Centrum Zdrowia Metabolicznego Pawel Bogdanski
🇵🇱Poznań, Poland
Centrum Kardiologiczne Pro Corde Sp. z o. o.
🇵🇱Wrocław, Poland
Niepubliczny Zaklad Opieki Zdrowotnej Centrum Medyczne OMEGA SP Z O O
🇵🇱Płock, Poland
NZOZ All - Med Centrum Medyczne Specjalistyczne Gabinety Lekarskie Marcin Ogorek
🇵🇱Łódź, Poland
First City Clinical Hospital n.a. E.E.Volosevich
🇷🇺Arkhangelsk, Russian Federation
Altay Regional Cardiology Dispensary, Cardiology Department for Patients with Acute Myocardial Infarction
🇷🇺Barnaul, Russian Federation
Chita State Medical Academy
🇷🇺Chita, Russian Federation
Kazan State Medical University based at City Clinical Hospital #7
🇷🇺Kazan, Russian Federation
Federal State Budget Institution "Scientific-Research Institute of Complex Problems of Cardiovascular Diseases
🇷🇺Kemerovo, Russian Federation
Medical Center Alliance
🇷🇺Kirovsk, Russian Federation
National Medical Research Center of Preventive Medicine
🇷🇺Moscow, Russian Federation
Krasnoyarsk State Medical University n.a. prof. V.F. Voino-Yasenetsky
🇷🇺Krasnoyarsk, Russian Federation
City Clinical Hospital #15 n.a. O.M. Filatov
🇷🇺Moscow, Russian Federation
Central Clinical Hospital of Russian Academy of Sciences
🇷🇺Moscow, Russian Federation
City Clinical Hospital n.a. M.E. Zhadkevich of Moscow Healthcare Department
🇷🇺Moscow, Russian Federation
National Medical Research Center of Cardiology - Department of Atherosclerosis
🇷🇺Moscow, Russian Federation
National Medical Research Center of Cardiology
🇷🇺Moscow, Russian Federation
City Clinical Hospital n.a. M.P. Konchalovskiy
🇷🇺Moscow, Russian Federation
Federal State Budget Institution "Outpatient Clinic #3" of Russian Federation President's Management Department
🇷🇺Moscow, Russian Federation
Clinical-diagnostic center Zdorovye
🇷🇺Rostov-on-Don, Russian Federation
North-Western State Medical University named after I.I. Mechnikov
🇷🇺Saint Petersburg, Russian Federation
Medical Technologies LLC
🇷🇺Saint Petersburg, Russian Federation
Limited Liability Company MedPomosch
🇷🇺Saint Petersburg, Russian Federation
City hospital #38 n.a. N.A. Semashko
🇷🇺Saint Petersburg, Russian Federation
Saratov State Medical University n. a. V.I. Razumovsky
🇷🇺Saratov, Russian Federation
Clinical Hospital #122 n. a. L.G. Sokolov of the Federal Medical Biological Agency
🇷🇺St. Petersburg, Russian Federation
Autonomous Institution of healthcare of the Voronezh region "Voronezh regional clinical consultative and diagnostic centre
🇷🇺Voronezh, Russian Federation
Tomsk National Research Medical Center of Russian Academy of Sciences
🇷🇺Tomsk, Russian Federation
Yaroslavl Regional Clinical Hospital for War Veterans - International Center on the Problems of the Elderly "Zdorovoe Dolgoletie"
🇷🇺Yaroslavl, Russian Federation
Municipal Healthcare Institution Kharkiv City Clinical Hospital #27, Intensive Therapy Department
🇺🇦Kharkiv, Ukraine
Kharkiv Medical Academy of Postgraduate Education
🇺🇦Kharkiv, Ukraine
Kharkiv Railway Clinic. Hosp.#1, Branch Office of "Healthcare Center" of PJSC "Ukr. Railways", Cardiology Depart #2
🇺🇦Kharkiv, Ukraine
Municipal Non-Commercial Enterprise "City Clinical Emergency Hospital n.a. prof. O.I. Meshchaninov of Kharkiv City Council
🇺🇦Kharkiv, Ukraine
Limited Liability Company Treatment and Diagnostic Center Adonis Plus, Outpatient Department
🇺🇦Kyiv, Ukraine
SI Institute of Gerontology n.a. D.F.Chebotarev NAMS of Ukraine, Cardiol. Un. of Clin. Physiology and Int. Organs Path. Dep-t., Gen. Ther.Unit
🇺🇦Kyiv, Ukraine
SI Institute of Gerontology n.a. D.F.Chebotarev NAMS of Ukraine, Cardiol. Un. of Clin. Physiology and Int. Organs Path. Dep-t
🇺🇦Kyiv, Ukraine
Municipal Institution City Clinical Hospital #3 n.a. prof. L.J. Aleinikova, Cardiology Intensive Therapy Department
🇺🇦Odesa, Ukraine
Centex Studies, Inc.
🇺🇸Houston, Texas, United States
Pioneer Research Solutions Inc.
🇺🇸Houston, Texas, United States
Midwest Institute for Clinical Research
🇺🇸Indianapolis, Indiana, United States
Palm Research Center, Inc.
🇺🇸Las Vegas, Nevada, United States
Sterling Research Group, Ltd. - Auburn
🇺🇸Cincinnati, Ohio, United States
Integrated Research Center
🇺🇸San Diego, California, United States
San Antonio Premier Internal Medicine
🇺🇸San Antonio, Texas, United States
Physician PrimeCare Research Institute, PLLC dba Health Texas Research Institute
🇺🇸San Antonio, Texas, United States
Bandera Family HealthCare Research, LLC (BFHC)
🇺🇸San Antonio, Texas, United States
Optimus Medical Group
🇺🇸San Francisco, California, United States
Professional Research Network of Kansas, LLC
🇺🇸Wichita, Kansas, United States
Elite Clinical Studies
🇺🇸Phoenix, Arizona, United States
COR Clinical Research, LLC.
🇺🇸Oklahoma City, Oklahoma, United States
South Oklahoma Heart Research
🇺🇸Oklahoma City, Oklahoma, United States
Central Research Associates, Inc.
🇺🇸Birmingham, Alabama, United States
Central Alabama Research
🇺🇸Birmingham, Alabama, United States
Cahaba Research, Inc.
🇺🇸Birmingham, Alabama, United States
Creekside Endocrine Associates, PC
🇺🇸Denver, Colorado, United States
Arrowhead Health Centers
🇺🇸Glendale, Arizona, United States
Clinical Research Institute of Arizona, LLC
🇺🇸Surprise, Arizona, United States
Brest Regional Hospital
🇧🇾Brest, Belarus
City Clinical Hospital #10
🇧🇾Minsk, Belarus
Medical Center Diamedical 2013 OOD
🇧🇬Dimitrovgrad, Bulgaria
Fifth Multiprofile Hospital for Active Treatment - Sofia EAD - Department of Endocrinology and Meteorism Diseases
🇧🇬Sofia, Bulgaria
Unimed Kakheti - Caraps Medline LLC
🇬🇪Tbilisi, Georgia
Clinical Trials Management LLC - Southshore
🇺🇸Metairie, Louisiana, United States
Gomel Regional Clinical Hospital
🇧🇾Gomel, Belarus
Fifth Multiprofile Hospital for Active Treatment - Sofia EAD - Department of Cardiology
🇧🇬Sofia, Bulgaria
Praktyka Lekarska Ewa Krzyzagorska
🇵🇱Poznań, Poland
Research Institute of Physiology and Fundamental Medicine
🇷🇺Novosibirsk, Russian Federation
Kharkiv Railway Clinic. Hosp.#1, Branch Office of Healthcare Center of PJSC Ukr. Railways, Cardiology Depart #1
🇺🇦Kharkiv, Ukraine
MD First Research
🇺🇸Lancaster, South Carolina, United States
Family Medicine of SayeBrook
🇺🇸Myrtle Beach, South Carolina, United States
Chattanooga Research & Medicine, PLLC
🇺🇸Chattanooga, Tennessee, United States
Minsk Scientific and Practice Center of Surgery, Transplantology and Hematology
🇧🇾Minsk, Belarus
Minsk Regional Clinical Hospital
🇧🇾Minsk, Belarus
Medical Center Orfey OOD
🇧🇬Stara Zagora, Bulgaria
Vitebsk Regional Clinical Hospital
🇧🇾Vitebsk, Belarus
Unimed Ajara LLC
🇬🇪Batumi, Georgia
Dr Lakatos Ferenc Belgyogyaszati-Kardiologiai Maganrendelo
🇭🇺Békéscsaba, Hungary
Clinmedica Research Omc Sp z o.o. Sp
🇵🇱Skierniewice, Poland
RC Medical LLC
🇷🇺Novosibirsk, Russian Federation
Orenburg State Medical University based at City Clinical Hospital #1
🇷🇺Orenburg, Russian Federation
BioTechService LLC
🇷🇺Saint Petersburg, Russian Federation
Pecsi Tudomanyegyetem Klinikai Kozpont I.sz. Belgyogyaszati Klinika
🇭🇺Pécs, Hungary
Northern Medical Clinical Center named after N.A. Semashko of the Federal Medical and Biological Agency
🇷🇺Arkhangelsk, Russian Federation
SALVIA Lekston i Madej s.j.
🇵🇱Katowice, Poland
Ural State Medical University based at Central City Clinical Hospital No.1 of Oktyabrskiy District
🇷🇺Ekaterinburg, Russian Federation
Consultative Diagnostic Center with Out-patient Clinic
🇷🇺Saint Petersburg, Russian Federation
Saint-Petersburg State Budget Healthcare Institution "City Pokrovskaya Hospital", Department of Cardiology N.3
🇷🇺Saint Petersburg, Russian Federation
AppleTreeClinics Sp. z o.o.
🇵🇱Łódź, Poland
Nzoz Salusmed
🇵🇱Łódź, Poland
Non-governmental Private Healthcare Institution "Scientific Clinical Centre of Open Joint-Stock Company Russian Railways" (JSC "RZD")
🇷🇺Moscow, Russian Federation
Interregional Clinical Diagnostic Center
🇷🇺Kazan, Russian Federation
City Clinical Hospital No.2
🇷🇺Novosibirsk, Russian Federation
Rostov-on-Don City Hospital of Emergency Care
🇷🇺Rostov-on-Don, Russian Federation
Clinic Complex JSC
🇷🇺Saint Petersburg, Russian Federation
Almazov National Medical Research Centre, Scientific Laboratory of Electrocardiology
🇷🇺Saint Petersburg, Russian Federation
Regional Clinical Cardiology Dispensary
🇷🇺Saratov, Russian Federation
Almazov National Medical Research Centre
🇷🇺St. Petersburg, Russian Federation
Ivano-Frankivsk Regional Clinical Cardiological Dispensary, Chronic Ischaemic Heart Disease Department
🇺🇦Ivano-Frankivs'k, Ukraine
Small Private Enterprise, Medical Centre Puls
🇺🇦Vinnytsya, Ukraine
Municipal Healthcare Institution Kharkiv City Outpatient Clinic #9, General Practice and Family Medicine Department #1
🇺🇦Kharkiv, Ukraine
Kyiv City Clinical Hospital #1, Urgent Cardiology Department
🇺🇦Kyiv, Ukraine
Municipal Institution City Clinical Hospital #6, Therapeutic Department
🇺🇦Zaporizhzhia, Ukraine
Meridien Research - Tampa
🇺🇸Tampa, Florida, United States
Meridien Research
🇺🇸Tampa, Florida, United States
DCT-AACT, LLC, dba Discovery Clinical Trials
🇺🇸Austin, Texas, United States
Kentucky Diabetes Endocrinology Center
🇺🇸Lexington, Kentucky, United States
The Research Group of Lexington, LLC
🇺🇸Lexington, Kentucky, United States
Lovelace Scientific Resources
🇺🇸Albuquerque, New Mexico, United States
Lynn Institute of the Ozarks
🇺🇸Little Rock, Arkansas, United States
Harleysville Medical Associates
🇺🇸Harleysville, Pennsylvania, United States
David M. Headley, MD P.A.
🇺🇸Port Gibson, Mississippi, United States